Clinical Trial Update: Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD) [Phase 4]

View source ↗

Summary

Phase 4 trial update on empagliflozin for Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD). The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• Empagliflozin (Jardiance) (empagliflozin)

Snippet

Sponsor: Hannover Medical School | Conditions: Autosomal Dominant Polycystic Kidney | Phase 4 | Status: ACTIVE_NOT_RECRUITING